Intangible Assets

3 Months Ended

Jan. 31, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Note 3. Intangible Assets

Intangible assets consisted of the following:


	January 31, 2026				October 31, 2025
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization

Intangible assets with definite lives:
Customer relationships	$	1,143.2	$	487.8	$	1,137.6	$	469.3
Composite intangible assets (1)	1,101.7		589.2		1,101.7		570.7
Technology	684.1		425.7		683.4		415.3
Trademarks	203.2		105.9		202.5		102.3
License and distribution rights and other	44.5		27.6		44.5		26.9
	3,176.7		$	1,636.2	3,169.7		$	1,584.5
Less: accumulated amortization and translation	1,636.2				1,584.5
Intangible assets with definite lives, net	1,540.5				1,585.2
Intangible assets with indefinite lives, net (2)	1.1				1.1
Total other intangibles, net	$	1,541.6			$	1,586.3

(1) Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.

(2) Intangible assets with indefinite lives include trademarks.

Balances include foreign currency translation adjustments.

As of January 31, 2026, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal Years:	(In millions)
Remainder of 2026	$	141.4
2027	174.8
2028	170.2
2029	166.0
2030	161.6
Thereafter	726.5
Total remaining amortization for intangible assets with definite lives	$	1,540.5

There was no material impairment of goodwill or intangible assets recorded in the three months ended January 31, 2026.